Del i serien Novel approaches to overcome cancer resistance to conventional therapies

Hypoxia-induced Tumor Heterogeneity and Immune Evasion

Clinical Interventions

Häftad, Engelska, 2027

2 289 kr

Kommande

Hypoxia-induced Tumor Heterogeneity and Immune Evasion: Clinical Interventions explores how hypoxic stress within the tumor microenvironment drives cancer progression, immune escape, and resistance to therapy. The volume integrates foundational and cutting-edge insights into tumor biology, immunology, and therapeutic innovation. It is structured into five parts, covering tumor heterogeneity, hypoxia-driven mechanisms, immune evasion, clinical diagnostics, and future directions. Topics include metabolic reprogramming, angiogenesis, immune suppression, and hypoxia-targeted therapies, with emphasis on translational relevance.

By bringing together global experts to examine how hypoxia shapes tumor evolution, alters immune responses, and influences treatment outcomes, this resource benefits researchers, clinicians, and advanced students by offering a comprehensive, up-to-date synthesis of a rapidly evolving field. It supports deeper understanding of tumor complexity and equips readers with knowledge to inform experimental design, clinical strategies, and therapeutic development in oncology.

Integrates hypoxia, tumor heterogeneity, and immune evasion to provide a unified framework for understanding resistance mechanisms in cancer
Presents cutting-edge research and clinical insights from global experts, offering a comprehensive view of tumor microenvironment dynamics
Equips researchers and clinicians with translational strategies to design innovative immunotherapies and improve patient outcomes

Produktinformation

Utgivningsdatum2027-02-01
Mått191 x 235 x undefined mm
Vikt450 g
FormatHäftad
SpråkEngelska
SerieNovel approaches to overcome cancer resistance to conventional therapies
Antal sidor330
FörlagElsevier Science
ISBN9780443485237

Tillhör följande kategorier

Biologi inom Naturvetenskap och teknik

Dr Bonavida has vast expertise and various reported publications in the field of tumor cell sensitization to chemotherapy (a total of greater than 500 publications) and in particular the novel role of Nitric Oxide (NO) donors in chemo-sensitization and reversal of drug resistance. In addition, he was the first scientist to co-organize an international meeting on the topic (First International Workshop on NO and Cancer, 2005).Dr. Salem Chouaib earned his Ph.D. in Immunology from the University of Pierre and Marie Curie (Paris VI) in 1983. He completed postdoctoral training at Memorial Sloan Kettering Cancer Center before joining INSERM and Institut Gustave Roussy, where he became Research Director and led the Tumor Immunology Lab. His research explores killer cell reactivity and tumor microenvironment dynamics, with a focus on hypoxia’s role in immune resistance. A pioneer in cancer immunotherapy, he founded the Thumbay Research Institute for Precision Medicine. Dr. Chouaib has received prestigious awards, including the French League Against Cancer Prize and the Presidential Prize in Biotechnology. He has mentored numerous postdocs, lectures at University Paris-Sud, and has published over 350 scientific works. He also serves as a guest lecturer, journal referee, and scientific advisor globally.

Part I: Introduction and Foundation1. Overview of Tumor Heterogeneity2. Molecular Basis of Hypoxia3. Tumor Heterogeneity4. Environmental Carcinogenesis and HypoxiaPart II: Hypoxia as a Driver of Tumor Heterogeneity5. Hypoxia-Induced Clonal Evolution6. Metabolic Reprogramming by Hypoxia7. Hypoxia-Driven Angiogenesis8. Epigenetics and Hypoxia9. Glycobiology, Vascular Biology and HypoxiaPart III: Immune Evasion Under Hypoxic Conditions10. Immune Landscape of Hypoxic Tumors11. Molecular Mechanisms of Immune Evasion12. Cross-talk Between Hypoxia and Immunotherapy ResistancePart IV: Translation and Clinical Perspectives13. Diagnostic and Imaging14. Hypoxia-Targeted Therapies15. Overcoming Immune Evasion Clinically16. Clinical Strategies to Overcome Immune EvasionPart V: Future Directions and Challenges17. Emerging Technologies18. Personalized Medicine and Precision Oncology19. Ethical and Regulatory ConsiderationsPart VI: Conclusions20. Overall Concluding Remarks21. References